3P Biopharmaceuticals is the first Spanish company of its kind to receive the good manufacturing practices (GMP) completion certificate granted by the Spanish Agency of Medicines and Health Products (AEMPS).
3P Biopharmaceuticals is the first Spanish company of its kind to receive the good manufacturing practices (GMP) completion certificate granted by the Spanish Agency of Medicines and Health Products (AEMPS). The Navarra Company, 3P Biopharmaceuticals has exceeded the AEMPS inspection with satisfactory conditions to obtain GMP certificate conforming to European Regulations. With this certificate, 3P Biopharmaceuticals has become the first Spanish company to develop biologics for third party companies to receive this GMP certification and to upgrade its authorization as a manufacturing, pharmaceutical laboratory of active pharmaceutical ingredients (API) obtained in 2009. This certificate assures that the medications are developed and controlled according to the quality regulations defined by the European Medicines Agency (EMA). The company is dedicated to the development and production of biologics for biological processes, consisting of bacterial fermentation, fungus and yeasts, and for mammalian cell culture for the production material of preclinical and clinical studies. As well, this company also offers process and product development for cell therapy.
3P Biopharmaceuticals was founded in 2006 and is looking to become submerged in internationalized processes. This company is actively looking for business opportunities in the United States and Europe. Last September, 3P Biopharmaceuticals participated in “Boston Landing,” a pilot program designed to facilitate the display of R&D and innovation and business development with biotechnology companies in the United States. Also, 3P Biopharmaceuticals has recently participated in a specialized biotechnology forum held in Abu Dhabi to explore the different opportunities in collaboration and alliance strategies in the biotechnology field with groups and investors from the United Arab Emirates.
With the support from all of its partners, the active participation of Navarra’s Development Society (Sodena) and following the Moderna Plan, the new Model of Economic Development for Navarra, and with its high quality demands and a high technological level, 3P Biopharamaceuticals wants to become more of an international market competitor.